Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder

European Archives of Psychiatry and Clinical Neuroscience

Volumn 258, Issue 3, 2008, Pages 171-178

  Lecrubier, Yves ^a   Dolberg, Ornah T ^b   Andersen, Henning F ^b   Weiller, Emmanuelle ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b H LUNDBECK A S   (Denmark)

Author keywords

Dimensional approach; Generalized anxiety disorder; Hamilton anxiety rating scale; Major depressive disorder; Montgomery sberg depression rating scale; Residual symptoms

Indexed keywords

ESCITALOPRAM;

ANXIETY; ARTICLE; CALCULATION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MENTAL CONCENTRATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SLEEP; TENSION; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CITALOPRAM; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 43349092976     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-007-0771-x     Document Type: Article

References (41)

1. Alexopoulos GS, Gordon J, Zhang D (2004) A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology 29(Suppl):S87
2. Alexopoulos GS, Privitera W, Ventura D, Bose A, Lenz SM, Wang Q (2004) Fixed dose of escitalopram (10 mg/day) and a flexible dosing regimen of sertraline (50-200 mg/day) in a randomised, double-blind comparison in depressed patients. World J Biol Psychiatry 5(Suppl 1):97
3. Allgulander C, Florea I, Huusom AKT (2006) Prevention of relapse in generalised anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:495-505
4. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington DC, USA
5. Andrews G, Neilson M, Hunt C, Stewart G, Kiloh LG (1990) Diagnosis, personality and the long-term outcome of depression. Br J Psychiatry 157:13-18
6. Baldwin D, Cooper J, Huusom AKT, Hindmarch I (2006) A double-blind, randomised controlled trial of escitalopram and paroxetine in the long-term treatment of major depressive disorder. Int Clin Psychopharmacol 21:159-169
7. Baldwin DS, Huusom AKT, Mæhlum E (2006) Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Brit J Psychiatry 189:264-272
8. Bech P, Kastrup M, Rafaelsen OJ (1986) Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand 73(Suppl 326):19-22
9. Bielski RJ, Ventura D, Chang C-C (2004) A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psych 65:1190-1196
10. Bielski RJ, Bose A, Chang C-C (2005) A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 17:65-69
11. Burke WJ, Gergel I, Bose A (2002) Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336
12. Colonna L, Reines EH, Andersen HF (2005) A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive patients with major depressive disorder. Curr Med Res Opin 21:1659-1668
13. Davidson JR, Bose A, Korotzer A, Zheng H (2004) Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19:234-240
14. Duncan-Jones P (1987) Modelling the aetiology of neurosis: long-term and short-term factors. In: Cooper B (ed) Psychiatric epidemiology, progress and prospects. Croom Helm, London, pp 178-191
15. Fava GA (1999) Subclinical symptoms in mood disorders: pathophysiological and therapeutic implications. Psychol Med 29:47-61
16. Forest Laboratories Inc. Summary available at: http://www. forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/ SCSR_SCT-MD-16_final.pdf. Accessed 12 Dec 2006
17. Goodman WK, Bose A, Wang Q (2005) Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 87:161-167
18. Gorman GM (1996-1997) Comorbid depression and anxiety spectrum disorders. Depress Anxiety 4:160-168
19. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
20. Horwath E, Johnson J, Klerman GL, Weissman MM (1992) Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry 49:817-823
21. Judd LL, Askikal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al (1998) Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predicator of rapid relapse. J Affect Disord 50:97-108
22. Kasper S, de Swart H, Andersen HF (2005) Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 13:884-891
23. Kasper S, Ninan P, Ventura D, Wang J (2005) Escitalopram in the treatment of severe depression. Eur Psychiatry 20(Suppl 1):S143
24. Kerr TA, Roth M, Schapira K (1974) Prediction of outcome in anxiety states and depressive illnesses. Br J Psychiatry 124:125-133
25. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19
26. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Harnett Sheehan K, Janavs J, Dunbar GC (1997) The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12:224-231
27. Lepola UM, Loft H, Reines EH (2003) Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18:211-217
28. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Brit J Psychiatry 134:382-389
29. Montgomery SA, Huusom AKT, Bothmer J (2004) A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50:57-64
30. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ 3rd, Rosenbaum JF, Fava M (1999) Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60:221-225
31. Norton PJ (2006) Toward a clinically-oriented model of anxiety disorders. Cogn Behav Ther 35:88-105
32. Olié J-P, Ménard F, Tonnoir B, Galinowski A (2006) A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress Anxiety. doi:10.1002/da.20207
33. Paykel ES (1998) Remission and residual symptomatology in major depression. Psychopathology 31:5-14
34. Rapaport MH, Bose A, Zheng H (2004) Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 65:44-49. Summary available at: http://www.forestclinicaltrials.com/CTR/CTRController/CTRView Pdf?_file_id=scsr/SCSR_SCT-MD-02_final.pdf. Accessed 12 Dec 2006
35. Regier DA, Rae DS, Narrow WE, Kaelber CT, Schatzberg AF (1998) Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry 173(Suppl 34):24-28
36. Roth M, Gurney C, Garside RF, Kerr TA, Schapira K (1972) Studies in the classification of affective disorders. The relationship between anxiety states and depressive illness. I. Br J Psychiatry 121:147-161
37. Shea MT, Leon AC, Mueller TI, Solomon DA, Warshaw MG, Keller MB (1996) Does major depression result in lasting personality change? Am J Psychiatry 153:1404-1410
38. Stein DJ, Andersen HF, Goodman WK (2005) Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry 17:71-75
39. Tyrer P (1989) Classification of neurosis. John Wiley & Sons, Chichester
40. Wade A, Lemming OM, Hedegaard KB (2002) Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17:95-102
41. Wittchen HU, Beesdo K, Bittner A, Goodwin RD (2003) Depressive episodes-evidence for a causal role of primary anxiety disorders? Eur Psychiatry 18:384-393